aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of "Buy" by Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) have received a consensus rating of "Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $20.20.

Several equities analysts recently commented on ATYR shares. HC Wainwright reiterated a "buy" rating and set a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. Wells Fargo & Company increased their target price on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday.

aTyr Pharma Price Performance

NASDAQ ATYR opened at $5.22 on Monday. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $3.99 and a 200 day simple moving average of $3.66. The company has a market cap of $464.58 million, a P/E ratio of -6.44 and a beta of 0.88. aTyr Pharma has a 1 year low of $1.46 and a 1 year high of $5.98.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. On average, sell-side analysts predict that aTyr Pharma will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Federated Hermes Inc. bought a new position in shares of aTyr Pharma in the 4th quarter valued at about $53,093,000. Point72 Asset Management L.P. acquired a new stake in shares of aTyr Pharma in the fourth quarter valued at approximately $17,677,000. Octagon Capital Advisors LP raised its holdings in shares of aTyr Pharma by 294.7% in the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock valued at $10,727,000 after purchasing an additional 2,652,000 shares during the last quarter. Tikvah Management LLC acquired a new stake in shares of aTyr Pharma in the fourth quarter valued at approximately $8,908,000. Finally, Woodline Partners LP acquired a new position in aTyr Pharma during the fourth quarter worth $6,092,000. Institutional investors own 61.72% of the company's stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.